ASCO 2023 Highlights: THOR, INDIGO and ADAURA

The American Society of Clinical Oncology Annual Meeting 2023 brought together thousands of experts in oncology to hear new data and discuss how to improve the diagnosis and treatment of patients with cancer. In this podcast, we hear from leading experts as they discuss some of the most groundbreaking trials from this year’s meeting. We will be joined by Yohann Loriot (Gustave Roussy, Villejuif, France), Karan Dixit (Northwestern Memorial Hospital, Chicago, IL), Roy S. Herbst (Yale School of Medicine, New Haven, CT), Ticiana Leal (Winship Cancer Institute of Emory University, Atlanta, GA), Jason Luke (University of Pittsburgh, Pittsburgh, PA). We will hear on the THOR study evaluating erdafitinib in metastatic urothelial cancer with FGFR alterations and the INDIGO trial of vorasidenib in residual or recurrent grade 2 glioma with an IDH1/2 mutation. There will also be discussion on the ADAURA trial investigating adjuvant osimertinib in resected EGFR‑mutated stage IB–IIIA non-small cell lung cancer, the LUNAR trial evaluating Tumor Treating Field therapy with standard of care in metastatic non-small cell lung cancer following platinum failure. The KEYNOTE-716 study, which assessed pembrolizumab in patients with high risk stage IIB or IIC cutaneous melanoma will also be discussed.